Premium
Treatment of Generalized Scleroderma with Inhibitors of Collagen Synthesis
Author(s) -
AsboeHansen Gustav
Publication year - 1982
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1982.tb02064.x
Subject(s) - medicine , scleroderma (fungus) , glycosaminoglycan , connective tissue , collagen disease , glutamine , penicillin , chlorpromazine , connective tissue disease , excretion , disease , antibiotics , pharmacology , gastroenterology , amino acid , immunology , autoimmune disease , pathology , biochemistry , chemistry , inoculation , anatomy
Clinical evaluation of scleroderma and the urinary excretion of collagen specific amino acids and uronic acid indicate disease activity and have become a guide for the treatment. During an experimental search for inhibitors of the synthesis of collagen and ground substance glycosaminoglycans, a few connective‐tissue active agents were selected for therapy of scleroderma: D‐penicilamine, benzyl‐penicillin‐diethylamino‐ethylester‐hydroiodide, l ‐glutamine, hydralazine, glucocorticoids, dextro‐thyroxine, l ‐dopa, diphenylhydantoin, chlorpromazine, and (+) catechine. Treatment for several years was required to bring about an arrest of progression in 89% of the patients, a regression in three‐quarters, and subtotal or total recovery in more than 40%. Indications of favorable prognosis are youth, short disease history, a high total dose of agent, and long duration of the treatment.